Skip to main content

Table 3 Summary of adverse events

From: Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

Events, n (%)

All patients (n = 40)

Any grade

Grade 3

Hypertension

26 (65.0%)

2 (5.0%)

Nausea

19 (47.5%)

0

Vomiting

17 (42.5%)

0

Hand-foot syndrome

13 (32.5%)

0

Abdominal pain

11 (27.5%)

0

White blood cell count decreased

9 (22.5%)

0

Fatigue

7 (17.5%)

0

Skin ulceration

6 (15.0%)

0

Gingival hemorrhaging or pain

6 (15.0%)

0

Proteinuria

4 (10.0%)

2 (5.0%)

Anorexia

4 (10.0%)

0

Alopecia

3 (7.5%)

0

Fever

1 (2.5%)

0